Published in PLoS One on June 09, 2016
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev (2002) 6.14
Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation (2001) 3.12
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation (2002) 2.78
ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm (2008) 2.75
Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet (2010) 2.34
Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J Am Coll Cardiol (2015) 1.66
Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis (1999) 1.63
Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation (1999) 1.57
Metabolomics as a tool for cardiac research. Nat Rev Cardiol (2011) 1.51
Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol (2005) 1.45
Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol (2008) 1.40
Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta (2010) 1.36
Prospective observational study of implantable cardioverter-defibrillators in primary prevention of sudden cardiac death: study design and cohort description. J Am Heart Assoc (2013) 1.30
Effects of prostaglandins E1, E2, A1, and F1-alpha on isolated vascular smooth muscle. Am J Physiol (1967) 1.26
17,18-epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase. Am J Respir Cell Mol Biol (2009) 1.20
Quantitative profiling of oxylipins through comprehensive LC-MS/MS analysis: application in cardiac surgery. Anal Bioanal Chem (2012) 1.18
Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung. Am J Physiol Lung Cell Mol Physiol (2008) 1.11
Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillators. Heart Rhythm (2008) 1.10
Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment. Am J Physiol Regul Integr Comp Physiol (2013) 1.05
The vasodilator 17,18-epoxyeicosatetraenoic acid targets the pore-forming BK alpha channel subunit in rodents. Exp Physiol (2007) 1.04
Comparison of free serum oxylipin concentrations in hyper- vs. normolipidemic men. Prostaglandins Leukot Essent Fatty Acids (2013) 0.98
Metabolomic identification of diagnostic plasma biomarkers in humans with chronic heart failure. Mol Biosyst (2013) 0.96
Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study. BMC Med Genomics (2010) 0.89
17(R),18(S)-epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: structure-activity relationships and stable analogues. J Med Chem (2011) 0.89
Effect of hormones on substrate preference in isolated rat heart. Am J Physiol (1968) 0.87
Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD). Circ Arrhythm Electrophysiol (2014) 0.85
The emerging role of oxylipins in thrombosis and diabetes. Front Pharmacol (2014) 0.85
An eicosanoid-centric view of atherothrombotic risk factors. Cell Mol Life Sci (2012) 0.84
n-3 Fatty acids and ventricular arrhythmias in patients with ischaemic heart disease and implantable cardioverter defibrillators. Europace (2005) 0.84
Mechanisms of sudden cardiac death: oxidants and metabolism. Circ Res (2015) 0.83
Cardiovascular effects of prostaglandins mediated by the central nervous system of the dog. Br J Pharmacol (1970) 0.83
19,20-EpDPE, a bioactive CYP450 metabolite of DHA monoacyglyceride, decreases Ca²⁺ sensitivity in human pulmonary arteries. Am J Physiol Heart Circ Physiol (2011) 0.82
Serum amine-based metabolites and their association with outcomes in primary prevention implantable cardioverter-defibrillator patients. Europace (2015) 0.78
Dietary supplementation with oils rich in (n-3) and (n-6) fatty acids influences in vivo levels of epidermal lipoxygenase products in guinea pigs. J Nutr (1990) 0.77